About Severe News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from About severe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In About Severe Today - Breaking & Trending Today

Xeris' Commercialization Partner for Ogluo®, Tetris Pharma Ltd, to Be Acquired by Arecor Therapeutics

Xeris' Commercialization Partner for Ogluo®, Tetris Pharma Ltd, to Be Acquired by Arecor Therapeutics
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom , Allison Wey , Gvoke Hypopen , Tetris Pharma , Paulr Edick , American Diabetes Association , Tetris Pharma Limited , Pyramid Laboratories Inc , Xeris Biopharma Holdings , Committee For Medicinal Products Human Use , Xeris Pharmaceuticals Inc , European Commission , Xeris Biopharma Holdings Inc , Regulatory Agency , Exchange Commission , Corporate Communications , European Medicines Agency , Biopharma Holdings , Arecor Therapeutics , United Kingdom Based , Xeri Chairman , European Economic Area , Medicinal Products , Human Use , Prescribing Information ,

Xeris Pharmaceuticals Enters Into an Exclusive License and Supply Agreement with Tetris Pharma Limited to Commercialize Ogluo® in Europe

Xeris Pharmaceuticals Enters Into an Exclusive License and Supply Agreement with Tetris Pharma Limited to Commercialize Ogluo® in Europe
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom , Shafiq Choudhary , Gvoke Hypopen , Strongbridge Biopharma , Tetris Pharma , Paulr Edick , American Diabetes Association , Tetris Pharma Limited , Pyramid Laboratories Inc , Xeris Biopharma Holdings , Committee For Medicinal Products Human Use , Xeris Pharmaceuticals Inc , Irish Companies , European Commission , Xeris Biopharma Holdings Inc , Regulatory Agency , Exchange Commission , Xeris Biopharma Holdings Or Strongbridge , European Medicines Agency , European Economic Area , Medicinal Products , Human Use , Prescribing Information , Xeris Pharmaceuticals , Costa Mesa ,

Xeris Pharmaceuticals, Inc.: Xeris Pharmaceuticals Receives U.K. MHRA Approval of Ogluo (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus

(2)
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the United Kingdom s Medicines and Healthcare Regulatory Agency (MHRA) has approved Ogluo (glucagon) injection for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.
In February, the European Commission (EC) approved Ogluo. As the EC decision was received after the end of the Brexit transition period, Xeris was required to complete a further administrative step in order to obtain a license in Great Britain. No re-examination of clinical data by MHRA was required. The marketing authorization is valid in the United Kingdom, all 27 countries of the European Union, Iceland, Norway, and Liechtenstein. ....

United States , United Kingdom , Great Britain , Allison Wey , Gvoke Hypopen , Xeris Pharmaceuticals Inc , European Commission , American Diabetes Association , Exchange Commission , European Union , Corporate Communications , European Medicines Agency , Pyramid Laboratories Inc , Healthcare Regulatory Agency , Committee For Medicinal Products Human Use , Xeris Pharmaceuticals , Medicinal Products , Human Use , Prescribing Information , Costa Mesa , About Severe , Private Securities Litigation Reform Act , Quarterly Report , Vice President , Investor Relations , ஒன்றுபட்டது மாநிலங்களில் ,

Xeris Pharmaceuticals Receives European Commission Approval of Ogluo (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus

Posted on
7691
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the European Commission (EC) has approved Ogluo™ (glucagon) injection for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The marketing authorisation is valid in all 27 countries of the European Union, plus Iceland, Norway, and Liechtenstein. As the EC decision was received after the end of the Brexit transition period, Xeris will complete a further administrative step in order to obtain a license in Great Britain. No re-examination of clinical data by the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) is expected. ....

United States , United Kingdom , Great Britain , Thomas Pieber , Allison Wey , Gvoke Hypopen , Novo Nordisk Glucagen , Paulr Edick , Xeris Pharmaceuticals , Division Of Endocrinology , American Diabetes Association , European Union , Pyramid Laboratories Inc , Committee For Medicinal Products Human Use , Xeris Pharmaceuticals Inc , Department Of Internal Medicine , European Commission , University Of Graz , Exchange Commission , Corporate Communications , European Medicines Agency , Healthcare Products Regulatory Agency , Business Wire , Chief Executive Officer , North America , Novo Nordisk ,

Xeris Pharmaceuticals Receives European Commission Approval of Ogluo™ (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus

Xeris Pharmaceuticals Receives European Commission Approval of Ogluo™ (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

United States , Thomas Pieber , Allison Wey , Gvoke Hypopen , Novo Nordisk Glucagen , Paulr Edick , Department Of Internal Medicine , Xeris Pharmaceuticals Inc , Xeris Pharmaceuticals , European Commission , Division Of Endocrinology , American Diabetes Association , Exchange Commission , University Of Graz , Corporate Communications , European Medicines Agency , Pyramid Laboratories Inc , Committee For Medicinal Products Human Use , Business Wire , Chief Executive Officer , North America , Novo Nordisk , Internal Medicine , Medical University , Medicinal Products , Human Use ,